W A L E S m e d i c a s p e c i a l

M E D I C A S P E C I A L 2 0 0 7

3

This MediWales Review ‘MedicaSpecial’ is your introduction to thethriving medical technology sector inWales. It includes a directory of all ofthose companies involved in the IBWtrade mission and pavilion at Medica2007 as well as a snapshot of someof the most exciting products andservices being offered by Welshcompanies in this sector.

Medica is the world’s largest medicaltrade fair and runs alongside theleading international fair for medicalmanufacturing supplies, ComPaMED.MEDICA and ComPaMED together willoccupy all 18 halls of the DüsseldorfExhibition Centre and organisersexpect over 4,300 exhibitors.

MEDICA covers the entire range ofoutpatient and in-patient health care,including: electrical medicine/medicaldevices ● laboratory technology/diagnostics ● physiotherapy/orthopaedic technology ● medicalsupplies (essential supplies andconsumables) ● information andcommunication technology ● textiles ●

medical furniture ● furnishings ●

facility management ● buildingservices.

At the same time, ComPaMEDaddresses all aspects of supplies tothe medical manufacturing sector:raw materials ● components ● parts ●

packaging ● services for use inmedical device production.

International Business Wales(IBW) is the Welsh AssemblyGovernment’s international trade andinvestment arm, forming part of theDepartment of Innovation, Enterpriseand Networks. It acts as the drivingforce in establishing alliances

between companies in Wales andtheir counterparts overseas. At thesame time it actively seeks outinward investment opportunities forclient companies looking to Europeand the UK as a preferredinternational business location.

The Welsh Assembly Governmentis a democratically elected body,which was established in May 1999.It has devolved powers andresponsibilities for developing andimplementing policies in Wales on abroad range of issues, includingeconomic development, education,the environment, agriculture,housing, roads and transport. TheWelsh Assembly works closely withthe UK Parliament in developingprimary legislation and has powers tointroduce secondary legislation of itsown.

MediWales has been active for oversixteen years and is therepresentative body for the medicalsector in Wales. Supported by theWelsh Assembly Government,MediWales is owned by its membersand led by directors drawn fromsenior industrialists and academics inWales. MediWales generates a uniqueenvironment for networking,collaboration and communicationbetween industry, higher educationand heath service members. This isdelivered through an active scheduleof seminar events and publications,supported by the MediWales websiteand maintained via constantcommunication with members andstakeholders. From this pivotal role,MediWales is able to represent bothits members and the wider sector togovernmental and internationalpartners.

MediWales is a founder member of Medilink UK, the network of regionalmedical technology organisations that represents the interests of around3000 organisations across the UK.

Medica 14-17 November 2007 - Messe Dusseldorf, Germany

The Welsh Pavilion: Hall 16 Stand 39Contents

Medical Technology 4

Wales Pavilion Directory 10-17

BB International 18

Haemair 19

JMJ 20

Molecular Light Technology 23

PDR 24

Wound Healing Research Unit 25

Zarlink 26

5 Schooner Way, Atlantic Wharf, Cardiff CF10 4DZ

T/F: 029 2047 3456

Email: debbie.laubach@mediwales.comcoralie.palmer@mediwales.comgwyn.tudor@mediwales.com

Web: www.mediwales.com

M E M B E R

5

M e d i c a S p e c i a l 2 0 0 7 W E L S H M E D I C A L T E C H N O L O G Y

4

The growth of Welsh medicaltechnology is galvanising everystage of the product developmentroute, across the full technologicalspectrum from commodities tohighly complex devices. This is agrowth not only of capacity but ofsophistication, both intechnological innovation and itseffective management.

Wales has long punched above itsweight in terms of its capacity forinnovation. Now Welsh companiesand academic institutions are alsoincreasingly engaging at a high levelwith financial institutions, whetherindigenous to Wales or from furtherafield. They’re therefore better atraising the capital required tofinance the cash-hungry and long-term nature of R&D in healthcare,through large-scale and oftenprivate sources.

This capability is matched withexpertise in the systemicmanagement of the innovationprocess. Even with simpler newproducts, getting them to marketrequires groups or individuals tocombine forces with others outsidetheir familiar territory. The morecomplex an innovative technology,the more collaboration becomesintegral to the process of itsdevelopment. Managing thatcollaborative process is increasinglyrecognised as a vital capability, andWelsh organisations are alreadydemonstrating a high level ofcompetence.

Meanwhile the economicenvironment is one that is nowproperly equipped to provide for thesector’s distinctive needs,particularly in relation to the highregulatory barriers and longtimescales characteristic ofcomplex innovative technologies.Companies can source within Walesthe full range of essential services,from clinical trials to productdesign to intellectual propertyexpertise.

In sum, there’s a well-developedworking pipeline for medicaldevices in Wales, from the researchfrontiers through productdevelopment to the market.Prospective partners can enter thispipeline at any point – and from anycountry: the healthcare market isby definition global.Interdisciplinary and commercialcollaborations cross internationalborders, and clinical trials are nowbeing conducted throughout theworld.

That ability to move acrossboundaries –scientific, professionaland geographical – is characteristicof the most active parts of thesector in Wales. The organisationsoutlined below demonstrate itsimpact on device innovations fromthe simplest to the most complex.This capability is one of thestrongest factors that go to makethe country such a promising basefor international partnerships.

The rapid growth of nanomedicineactivities in Wales show native

organisations working at thehighest international level. TheCardiff University NanoscienceNetwork (CuNN) connects researchinterests from basic sciences toregulation and ethics. It includesthe Centre for PolymerTherapeutics, which put theworld’s first polymer-based anti-cancer nanopharmaeutical intoclinical trial in 1994. The Centre’sDirector led the mapping out ofnanomedicine’s future for theEuropean Science Foundation’s2005 Forward Look report, and wasCourse Director for the inauguralESF Summer School inNanomedicine at Cardiff in June ofthis year.

At Swansea University, theNanoHealth partnership bringstogether the MultidisciplinaryNanotechnology Centre (MNC) andthe recently-established Instituteof Life Science (ILS). The MNC is ahub for the most advancednanotechnology researchthroughout Wales and the site forcutting-edge facilities needed by itspartners. The ILS is assembling ateam of internationally acclaimedscientists across a range of relateddisciplines and its facilities includeone of the largest IBMsupercomputers in Europe, ‘BlueC’. The NanoHealth partnership’sfour major areas of imaging,modelling, tissue repair andmedical devices show the essentialinteractivity of different fields ofexpertise that is typical of highlycomplex innovations.

Swansea’s ILS is also home to thenew Boots Centre for Innovation,which will be helping researchersand entrepreneurs from around theworld to develop new products. Apartnership deal between AllianceBoots plc and venture capitalistsLongbow Capital LLP will offer theentrepreneurs access to investmentfunding. The Centre has outlined10 key strategic areas for productresearch and development, whichinclude pain relief, skin treatments,diabetes and healthy ageing.

Boots has invested £3 million intothe Centre, and believes that theprospect of distribution throughoutAlliance Boots’ massiveinternational network will draw inthe most talented inventors tocreate new products for them. Themanagement team is alreadyattracting ideas from countriesaround the world including China,South Africa, America andDenmark.

National and internationalcollaboration is likewise adistinguishing feature of ZZaarrlliinnkkSSeemmiiccoonndduuccttoorr, providing leading-edge semiconductor solutions forvoice, enterprise, broadband andwireless communications. As partof the ‘Healthy Aims’ EUFramework VI project, which isdeveloping a range of medicalimplants for the ageing anddisabled population, Zarlink isfocusing on novel in-body antennadesign and ultra-low-powercommunications systems forimplanted devices, such as hearingaids and muscle stimulators.

Meanwhile as a member of theEuropean SHIFT project (SmartHigh-Integration Flex Technologies)Zarlink is working on flexiblepackaging technology for thepersonal medical device market,and its first SHIFT-enabled productdemonstrator will be available atthe end of 2007.

The company is also leading a UK-based consortium of companiesthat is developing an in-body

microgenerator. The device willconvert energy from human body movement into powerfor implanted medical devices,including pacemakers, electricalstimulators, instrumented jointsand body area networkapplications. The project hasreceived £500,000 in funding fromthe UK Department of Trade andIndustry (DTI), which will be match-funded by the consortium.

Welsh medical technology reaches out

7

Responsiveness to clinical need isan essential part of collaborativeproductivity, and the ability totranslate needs into workabledevices is equally visible in thedevelopment of simpler medicaldevices that have significant impact.Spin-out company ShakerScopeprovides the classic example ofsuch a product. The ShakerScope isan eco-friendly, battery-free lightsource, which enables a range ofessential medical instruments –including laryngoscope, otoscopeand opthalmoscope – to be used indemanding environments anddeveloping countries.

Developed out of a clinical settingby consultant anaesthetists, theproduct has been supportedthroughout by Welsh organisationalnetworks, receiving product designservices and prototyping from PDR,grants from the Welsh AssemblyGovernment’s Smart Cymruinitiative, project managementsupport from Welsh Innovations inHealthcare (WisH), and access tonetworks and collaborativeopportunities through Mediwales.

One of the most interesting modelsfor bridging the clinical-commercialdivide is that developed by ProfessorGerfried Giebel in Germany and nowbeing applied in Wales. The GiebelRound is a process of regular smallmeetings between equal numbers ofclinicians and industrialists, held onactive sites at clinical and companypremises alternately. These real-life environments demonstrate thedifferent needs and forces at work in

the clinical and commercial worlds,producing better – and speedier –solutions for the problems involved.

Now funding from the EU ‘Innofire’programme has enabled WrexhamCounty Borough Council toestablish its own Giebel Round inNorth Wales. Already thesemeetings have resulted in fourinformal partnerships that are nowworking on new products. TheWrexham Giebel Rounddemonstrates how a Europe-wideexample of best practice can besuccessfully applied at the locallevel, to bring through innovativemarketable devices that meetimportant clinical needs.

In terms of both national andinternational networking andcollaboration, the annual BioWalesconference has become a landmarkin the Wales bioscience calendar,bringing together top names in thesector from an increasingly

international pool of both speakersand delegates. Keynote speaker atBiowales 2008 will be HealthMinister Lord Ara Darzi, whoseinterim review of the NHS has justbeen published.

At the heart of BioWales is thebrokerage event organised by theWales Innovation Relay Centre(WIRC), Welsh arm of theEuropean-wide IRC network thatfosters transnational technologytransfer and innovative services. At each year’s BioWales brokerage,WIRC’s specialist expertise hasconsistently effected successfultechnology transfer agreementsbetween academic institutions,multi-nationals and consortia.

This brief scan indicates the highlyactive and diverse commercialprofile, leading-edge researchcapability and well-developedsupport infrastructure that haveenabled Welsh medical technologyto consolidate its position in theinternational sector. With a strongfocus on collaborating to innovate,and expertise in managing both thehuman and technological processesinvolved, Wales offers substantialopportunities for capitalising onthese native assets to prospectivepartners both within and beyond itsborders.

Medical Solutions from

GX Design EngineersThe MayfieldUsk MonmouthshireNP15 1SYUnited Kingdom

Tel +44 (0)1291 673437 Fax +44 (0)1291 673438E-mail claire@gxl.co.uk Web www.gxl.co.uk

For all enquiries contact Claire Banks

Established in 1987, GX is an independent design consultancy

specialising in the original design and development of ground

breaking products, advanced instruments and machines.

GX has an extensive range of in-house services which include:

Industrial Design

Mechanical Design

Electronic Design

Software Design

Optronics Design

Rapid Prototyping

The award winning design consultants

11

M e d i c a S p e c i a l 2 0 0 7 W A L E S P A V I L I O N D I R E C T O R Y

10

Axiom Manufacturing Services LtdTechnology Park, NewbridgeNewport NP11 5ANTel: 01495 242130Fax: 01495 242096Email: garethb@axiom-ms.comWeb: www.axiom-ms-com

Axiom Manufacturing Services focuses on providing contract electronicmanufacturing services (EMS) to original equipment manufacturers (OEM’s)who do not want to manufacture some or all of their products in house.

A complete range of electronics manufacturing services are available fromdesign support, prototyping, new product introduction, PCB assembly, subassembly, product assembly, test, warehousing and logistics through to aftermarket services which includes repair and rework.Objectives at MedicaAxiom are visiting Medica to network, look for new customers and learn moreabout the exhibition

BBI HealthcareUnit A Kestrel Way, Garngoch Ind EstGorseinon, Swansea SA4 9WNTel: 01792 229333Fax: 01792 897311Mobile: 0799 062889Email: karlmorris@bbihealthcare.comWeb: www.bbihealthcare.com

Welsh Assembly Government Department for the Economy andTransport, Trafalgar House, 5 Fitzalan Place, Cardiff, Wales CF24 0ED United KingdomTel: +44 29 2082 8694Fax: +44 2044 2696Email: jose.constantino@wales.gsi.gov.uk Web: www.ibwales.com

International Business Wales (IBW) is the Welsh Assembly Government’sinternational trade and investment arm. It forms part of the Departmentfor the Economy and Transport, and acts as the driving force in establishingalliances between companies in Wales and their counterparts overseas,whilst actively seeking out inward investment opportunities for clientcompanies looking to Europe and the UK as a preferred internationalbusiness location.

Jose is in charge of the International Trade activities in the EU markets. Hemanages a network of business consultants based in key overseasmarkets and has overall responsibility for delivering IBW’s InternationalEvents programme in Europe.

Jose ConstantinoRegional Manager - Europe,

BCB International LtdUnit 7 Clydesmuir Road, Ind EstTremorfaCardiff CF24 2QSTel: 029 20 433715e-mail: la@bcbin.comWeb: www.bcbin.com

Biocatalysts Ltd, Unit 1, Cefn CoedParc Nantgarw, Cardiff CF15 7QQTel: 01443 843712Dax: 01443 846500Mobile: 07974 922679Email: theresac@biocats.comWeb: www.biocatalysts.com

Biplas Medical Llantrisant Business Park, LlantrisantRhonnda Cynon Taff, CF72 8LFTel: 01443 237654Fax: 01443 237433Email: richard.bedwell@biplas.comWeb: www.biplas.com

Blizzard Protection Systems Limited Unit 2, Coed y Parc Industrial Estate Bethesda, Gwynedd LL57 4YY United Kingdom Tel: +44 (0)1248 600666 Fax:+44[0] 1248 600444Web: www.blizzardsurvival.com Email: info@blizzardsurvival.com

Blizzard Protection Systems Limited based in Bethesda, North Wales develops,manufactures & markets a range of emergency survival products under the brandname Blizzard Survival. These products are used in the prevention & treatment ofhypothermia in the evacuation of casualties in military, medical, emergencyservices and the outdoor sectors.

Manufactured from Blizzard’s exclusive “Reflexcell” material the productsrepresent a step change in the way both civilian & military trauma casualties canbe treated. Ultra light, compact, portable and reusable, the products are unique,weight for weight warmer than goose down, yet 100% weatherproof. Blizzard kit isnow recommended as the first choice for keeping casualties warm by the NationalAssociation of Emergency Medical Technicians and every medic in each of theUnited States Special Forces is being issued with the military version of theBlizzard Survival Blanket.Objectives at MedicaTo promote and develop the Blizzard Survival brand, engage potential customersand expand our presence in new markets

Innovative design and development company with manufacturing capability inplastic injection moulding. We develop devices using the latest technology inpolymer and metallurgy with the required electronics using our associated partner.Offering know how and expertise based on our engineering and knowledge of awide range of processes, capable of manufacturing the end product at a costeffective price. We are currently working on single use disposable devices in thefield of laparoscopy, gynaecology and urology. We are working with leadingclinicians in these areas to enabling the use of appropriate technology andprocesses to develop devices with patient need being the priority. Opportunities forpartnerships are sort in the medical/healthcare arena enabling early stage devicesand systems be developed, trialled and finally marketed via our distributionpartners. We design and develop specialised packaging in the areas of radiologyand bioscience.

Biocatalysts Ltd is a specialist enzyme company based in the United Kingdom. Itprimarily manufactures enzymes for the Food and Diagnostic Kit markets but isdifferent from the majority of enzyme companies in the world market because of itsfocus on custom-tailoring or developing “bespoke” enzyme systems for individualclients. Driven by its obsession with superior customer service Biocatalysts havegained an enviable reputation in the speciality enzyme market. The diagnosticenzyme range covers enzymes to test for a wide range of conditions and fulldetails are available at www.biocatalysts.com

BCB International Ltd has been a prime contractor to the life raft and lifeboatindustry for over 50 years. We are a manufacturer and designer of survivalequipment, primarily for the marine and military markets. Over 80% of BCBproduction is exported predominately to Europe, the Middle and Far East. BCB hasa continuous and never ending innovation policy that has resulted in hundreds ofquality innovative product over the years.Objectives at Medica: One of the many products we supply to our marine market is our solas approvedmedical first aid kits, as an ISO9001:2000 approved company we are always lookingto form good working relationships with quality approved suppliers of medicalproducts, our requirements are in the first instance to source new suppliers forexisting medical products where current suppliers are failing us, however ourother aim is to identify new exiting innovative products that fit within our productrange and build new relationships with the designers/manufacturers to ensure weare always offering our customers the best and latest inventions that are availableon the market to ensure safety of life in hostile environments.

Biocatalysts

Biplas Medical

BCB InternationalInternational Business Wales

Axiom

BBI Healthcare

BBI Healthcare is a leading provider of diabetes care products to the globalmarket place. As part of the successful BBI Holdings group (BBInternational,Biozyme, Seravac), the division was set up to source and develop diabetessolutions to complement the group’s range of diagnostic services. Since thesouth Wales based healthcare company was established in 2006, it alreadyhas a proven track record of commercializing diagnostic and healthcareproducts to the international market place.

BBI Healthcare is currently looking for European distributors for its glucosetablets and leading GlucoGel brand, which has been widely available throughthe NHS since 1984.

The company is also seeking new products which can be channeled througha number of territories including UK, Europe, North America and Australasia.

Blizzard Survival

Lisa OwenPurchasing Manager

Gareth BeckettSenior Accounts Manager

Karl John Stanley MorrisSales Manager

Stuart Ian West, Managing Director

Howard KendrickGeneral Manager

TTems Ltd Rogerstone-South WalesTregwilym Industrial Estate,Rogerstone, South Wales NP10 9YATel: +44 (0) 1633 892345 Fax:+44 (0) 1633 895755Email:info@ttems.comWeb: www.ttems.com

Abtest is an independent test house, part of the global electronic company,TT electronics plc. Certified UKAS, BS9000 and IECQ/CECC, Abtest workswith customers in the automotive, telecommunications, medical, defence,aerospace and consumer markets. We specialise in climatic and dynamicenvironmental testing, functional and in-circuit test development, productinvestigative testing, electrical and mechanical calibration service. Equippedto handle a great range of standard tests, Abtest comes into its own whenasked to custom-design new test regimes. The great range of technicalskills of our staff and assets like our tool room are a major advantage.Abtest performs tests on products where quality, security, confidence andconfidentiality are of the highest importance.Objectives at Medica: To increase market awareness and expand our customer base.

AB Test

Richard Bedwell Managing Director

13

M e d i c a S p e c i a l 2 0 0 7 W A L E S P A V I L I O N D I R E C T O R Y

12

Cardiff Business Technology Centre LtdSenghenydd RoadCardiff CF24 4AYTel: 029 2087 2659Fax: 02920 87 3233 Web: cbtc.co.ukEmail: d.pascoe@cardiff.gov.uk

Cardiff Business Technology Centre

Cardiff Business Technology Centre provides flexible premises, business support andfinancial assistance, directly and via its partners, to help new start high technologycompanies grow successfully; and in concert with its sister centre, the CardiffMedicentre - located on the University Hospital of Wales campus adjacant to theCardiff Medical School (part of Cardiff University), looks to grow on companies intoCardiff and the City Region. With the proposed redevelopment of the Centre toprovide a 100,000sq ft (10,000sq m) innovation centre closeby the main CardiffUniversity campus and the increasing internationalization of the commercialexploitation of new technologies, the company is looking at Medica to start to searchout new contacts in international markets to meet this expanded and growing role.

Cardiff Medi Centre

Cardiff Medi CentreHeath ParkCardiffCF14 4UJTel: 02920 87 3157Fax: 02920 87 3233Mobile: 07855 857 664Email: mcoleman@cardiff.gov.uk

Cardiff Medicentre offers assistance in the development and commercial exploitationof innovative technology in the medical, life and bio-sciences. It is a joint venture ofCardiff University, Economic Development of Cardiff Council , the Cardiff and ValeNHS Trust and the Welsh Assembly Government; who each are able to providesupport. Flexible accommodation, financial assistance and business support whereneeded offer an unrivalled package for early stage projects to reach successfulfruition and to relocate into the city region. The centre is located on the main MedicalSchool campus with units available from 280 sq ft upwards.Objectives at MedicaTo clarify the opportunities in international markets for the Cardiff offering.

Cellpath

Cellpath80 Mochdre Enterprise ParkNewtown, Powys SY16 4LETel: 01686 611333Fax: 01686 622946Email: Philip@cellpath.co.ukWeb: www.cellpath.co.uk

Cellpath has established itself as a dynamic innovative company, and has anenviable reputation over 25 years for reliability and customer service in its role asmarket leading supplier of cellular pathology consumables.

In addition to supplying a comprehensive range of pathology consumables,Cellpath continues to be at the fore-front of the design and development of newproducts. Cellpath has the resources to offer contract manufacturing, processingand packaging, as well as warehouse and distribution for customers looking tooutsource these labour-intensive operations.OObbjjeeccttiivveess aatt MMeeddiiccaaIncrease export market by meeting potential and existing suppliers, distributorsand customers

Enfis

Philip WebberManaging Director

Paul WebberFinance Director

Brian ReidExport Sales Manager

Ali YilmazSales Manager

Enfis LtdTechnium 2King’s Road, Swansea WaterfrontSwansea SA1 8PJ

Enfis is a world-class provider and manufacturer of High Power LED light enginesand arrays across a wide range of wavelengths; including white light, for use inmedical and healthcare applications.

With over 15 International patents, Enfis’s LED products can also be boughtglobally through distributors such as Digi-Key (www.digi-key.com) and Pacer(www.pacer.co.uk)

Examples of medical applications that have already benefited from Enfis’s LEDtechnology in preference to older traditional forms of lighting include:● Neonatal treatment of Hyperbilirubinemia (jaundice in new born babies)● Operating Room and Examination lighting● Dental whitening and composite curing

Haemair

Haemair LtdUnit 212 Digital TechniumSwansea UniversitySwansea SA2 8PPTel: 01792 602466Mobile: 07970 218709Email: sbrown@haemair.comWeb: www.haemair.com

The Haemair mission is to produce respiratory aids that range from devices thatsupport respiration for patients with deficient lungs via an easily reversible fullyexternal device to a prosthetic device that may replace human lungs.

The basis of the device is a blood/air mass exchanger. This exchanger takes carbondioxide from the blood and transfers oxygen into the blood. It is compact, portable andsuitable for conscious, active patients.

Unlike most conventional treatments for lung deficiency, the devices do NOT usethe lungs, thus they allow deficient lungs to rest and recover.

The product supports life by direct blood/air mass exchange. The novel featuresinclude incorporation of a control system that integrates with the body’s naturalcontrol mechanisms to respond to respiratory demand.

Also, It employs natural air. Use of natural air has the benefit that the patient isnot connected to an oxygen supply.Objectives at MedicaTo develop links with further companies in the medical device industry.

David Pascoe

Mark Stephen ColemanSenior Economic Development Officer

Steve BrownSenior Engineer

GX Design Ltd

Claire BanksSales Consultant

The MayfieldUsk, Monmouthshire, WalesNP15 1SY United KingdomTel: +44 1291 673437Fax: +44 1291 673438 Email: claire@gxl.co.uk Web: www.gxl.co.uk

GX Design Engineers offers a medical product design and development service fromconcept through to manufacture. This includes electronic, mechanical, optics,industrial and software design, prototyping and CAD animations. GX combinespractical engineering solutions with creativity, innovation and focus within keyservices including industrial design, mechanical design, electronic hardware,design, software design, optical & optronic design and rapid prototyping. Medicalprojects have been undertaken for clients including Bayer Diagnostics, GyrusMedical, Rhytec, CLP, Pall, Medical Support Systems, Morecare and British Gas. GXDesign also provide FEA, Cosmos, Research for user, markets, materials andprocesses, branding, packaging and literature, model making and CAD animations.Objectives at MedicaTo introduce GX to the major medical manufacturing companies in Europe.

Holtain

CrosswellCrymych, Pembrokeshire SA41 3UFWales United KingdomTel: ++44 (0)1239 891656Fax: ++44 (0)1239 891453Email sales@holtain.co.ukWeb: www.anthropometer.com

SO9001:2000 Accredited, Holtain Ltd manufacturer of the world famous “Harpenden”range of anthropometric instruments.

The “Harpenden” instruments, which have been developed in close collaborationwith the University of London Institute of Child Health, are counter recording andthey give accurate and direct readings to the nearest millimetre.

“Harpenden” instruments are so effortless in operation as to make possible acontrol of measurement unrealisable with conventional anthropometric instrumentsShould our range of items not meet the requirements of any project, please contactus and we will be more than happy to discuss modification or custom designedinstrument.

Niamh HoldingKenneth Dalziel

Boots Centre for InnovationInstitute of Life ScienceSwansea University, Singleton ParkSwansea SA2 8PPTel: 01792 513722Email: Yvonne.james@bootsinnovation.comWeb: www.bootsinnovation.com

Boots Centre for Innovation

The Boots Centre for Innovation can provide support and funding for thedevelopment of innovative products and technologies. We are particularlyinterested to meet people with new ideas and products to address the followingconsumer needs: •Improve and maintain the health, look and feel of skin •Improve the health and appearance of teeth and gums •Devices that enable people to monitor key aspects of their health •Improve the health, appearance and comfort of eyes •Improve digestive health issues, particularly related to stress, poor diet and obesity •Minimise the severity and duration of pain •Improve quality of sleep for everyone [including pregnant women, babies and the

elderly •Minimise the complications of living with diabetes •Anti-ageing devices and products for mind and body •Create more convenient methods of using medicines and health products

Yvonne James / Louise Bryce

15

M e d i c a S p e c i a l 2 0 0 7 W A L E S P A V I L I O N D I R E C T O R Y

Manufacturing Engineering Centre

Manufacturing Engineering CentreCardiff University, Queen’s BuildingNewport Rd, Cardiff, CF24 3AATel - 02920 87 4641Mobile - 07940 077 197Web: www.mec.cf.ac.ukEmail: manufacturing@cf.ac.uk

MicroBridge is an open access service for industry and offers a comprehensive rangeof micro and nano structuring and machining capability for non-silicon materials.This includes micro and nano machining and micro fabrication and replication ofstructures from a few tens of nano metres to 1 mm. MicroBridge bridges the gapbetween conventional precision micro machining and the lithographic/direct writesemiconductor patterning technologies for a wide range of different materials – fromhard metals to softer polymers and for difficult-to-machine ceramics and glass. Arange of process technologies are being offered, including picosecond laser ablation,micro electro-discharge machining, focussed ion-beam milling and nano imprintingand polymer replication processes.

Nano and micro engineering offers a whole new range of product functionality thatis not possible in larger scale. Sensors, medical and dental devices, health care andpharmaceuticals, automotive components, aerospace are a few sectors that arecurrently exploiting the opportunities offered by micro and nano engineering.OObbjjeeccttiivveess aatt MMeeddiiccaaTo create awareness of what can be achieved from the MEC equipment and toincrease the revenue from such leading edge technology.

Medical Device Consultancy

Medical Device Consultancy6 Bessborough DriveCardiff, CF11 8NEWales, UKTel: +44 (0)29 2022 1640 Mobile +44 (0)7739 733177Web: www.medicaldeviceconsultancy.co.ukEmail: lewlink@btclick.com

Medical Device Consultancy provides specialist business reviews, planning anddevelopment consultancy to medical device, in vitro diagnostic (IVD) and relatedcompanies, including partner search and selection projects. Associates have particularstrengths in medical device and in vitro diagnostic (IVD) regulatory compliance forEurope and North America, quality system establishment / improvement, auditing,process, product and software validation, marketing and product management.Medical Device Consultancy works with a specialist associates to provide in-depthassistance with:•Strategic business development and marketing advice.•Preparation for regulatory inspections or Notified Body quality system audits.•Regulatory documentation.•Can provide both European Authorised Representative and US Agent services.•Getting your medical device from concept to market – profitably.Objectives at MedicaTo meet possible new clients and associates.

Trevor LewisPrincipal Consultant

Geraint EvansBusiness Manager

Nightingale Care Beds Ltd

Nightingale Care Beds LtdUnit 20 Abenbury WayWrexham Industrial EstateWrexham LL13 9UZTel. +44 1978 661699Fax +44 1978 661705Email. kevineames@nightingalebeds.co.uk

Nightingale Care Beds produce specialist hospital beds and equipment to the NGS,private hospitals and other care facilities for the clinically obese (bariatric) andpatients at risk of developing pressure ulcers.

Pressure Area Care is provided throughout the ProAxis range of electric profiling ofhospital beds by using of a Visco elastic mattress and the SMART PressureRedistribution System. This is programmable movement of the mattress platformwhich provides dynamic redistribution of pressure.

ProAxis Plus is a bariatric hospital bed, is supported by compatible, high qualitybatriatric equipment including patient hoists, rise/recline and static chairs,commodes, wheelchairs, walking frames and slings.Objectives at MedicaNightingale are actively looking for new innovative ideas to enhance their currentrange of patient care products.

We are also looking to form strategic relationships with companies throughoutEurope who share our ethos of quality, value and service.

Kevin EamesBusiness Development Manager

PDR

PDRUWICWestern AvenueCardiff CF5 2YBTel: 02920 416725Fax: 02920 416973Email: ASpiteri-pdr@uwic.ac.ukWeb: www.pdronline.co.uk

An established and world renowned centre for innovation, PDR undertakes world classdesign, engineering and product development support, from conceptual and pre-market analysis, right through to detail and tool design to prototype, verification, batchmanufacture and product launch.

Combining the latest in research and knowledge with strong commercial discipline,experience and focus, PDR brings together the latest technologies and facilities withexperienced, award-winning designers, engineers and technicians, to createunparalleled capability. Both the breadth and depth of experience and capability at PDRis impossible to find in a single location elsewhere in Europe.

PDR has extensive experience in medical sector, and since its establishment over 13years ago has helped many hundreds of companies, from major bluechips to start ups,to successfully innovate and grow.Objectives at Medica:•To strengthen and develop new client relationships •To gain a stronger presence in the medical industry•To promote PDR’s new service offerings•To promote new technologies and processes available in-house at PDR that will

benefit product development and innovation in the medical sector

Angela Spiteri Marketing ExecutiveJulie Stephens Commercial ManagerJarred EvansCommercial Director

Institute of Life Science

Institute of Life ScienceSchool of Medicine, Swansea UniversitySingleton Park, Swansea SA2 8PPTel: 01792 295202Fax: 01792 295676Mobile: 07711379116Eamil: k.m.hawkins@swansea.ac.ukWeb: http://www.medicine.swan.ac.uk/

The Institute of Life Science, is a purpose-built facility home to the School ofMedicine’s research enterprise, housing internationally-recognised academics andscientists working at the boundaries of traditional disciplines. The institute createsan environment that draws on research expertise from the Schools of Science,Engineering and Business at Swansea University, enabling the School of Medicine topush forward the frontiers of knowledge with integrated support.

Underpinning this innovative environment is a specialist business team, focused onbuilding commercial-academic links in support of the Institute’s research and takingadvances from the laboratory into hospitals, surgeries and homes. Opportunities willarise from areas such as research collaboration, intellectual property licensing,spinout companies and inward investment.Objectives at MedicaTo exploit research outcomes with internationally leading industries.To expand collaboration with leading international research centres.

14

JMJ

JMJ LaboratoriesJMJ Laboratories,Gavenny Court, Brecon Road,Abergavenny, Monmouthshire NP7 7RXUnited KingdomTel: +44 (0) 1873 856688Fax: +44 (0)1873 856688Email: info@jmjlabs.co.ukWeb: www.jmjlabs.co.uk

JMJ Laboratories Ltd provides pathology and workplace drug testing services to awide variety of clients in the UK and overseas. Our fully accredited analytical servicesare supported by experts who can also provide advice and guidance for customers.

In conjunction with our parent company – Synergy Healthcare - we can offerassistance with infection control programmes by providing fast results for MRSAusing the latest technology.

Our Toxicology department can help with implementing drug and alcohol policies,drug awareness and testing urine, hair or saliva samples for illegal drugs. JMJ alsohas a sample collection service which operates 24/7, enabling tests to be carried outat any time, anywhere.

Alison PayneManaging Director

Karl Michael HawkinsResearch Fellow

17

M e d i c a S p e c i a l 2 0 0 7 W A L E S P A V I L I O N D I R E C T O R Y

16

TT electronic manufacturing services Ltd

TT electronic manufacturing services Ltd(TTems) Tregwilym industrial estateRogerstone, Newport NP10 9YATel: 01633 892345Fax: 01633 895755Email: info@ttems.comWeb:www.ttems.com

Delivering electronic manufacturing solutions. As the largest UK-owned EMSproviders, TT electronic manufacturing services Ltd (TTems) is an establishedmanufacturer of electronic & electromechanical assemblies and finished products tothe defence, telecommunications, automotive, medical and industrial sector. Itscomplete range of value added services covers design support and processoptimisation, turnkey manufacturing and tailored logistics through to after salessupport. In addition it provides life-cycle cost-efficiency combining UK-based NPI andlow- to mid-volume production with a high volume low cost manufacture from its ownfacilities in China and Malaysia, both with UK programme-management. TTemsdemonstrates commitment to its customers through the implementation of lean andsix-sigma technique and led to accreditation such as : ISO9001:2000, ISO14001,TS16949 and a Kitemark for quality standard IPC-A-610D.

Derek BennettBusiness Development Manager

Wound Healing Research Unit

Wound Healing Research UnitUpper Ground Floor, School of MedicineCardiff University, Heath ParkCardiff CF14 4XNTel: +44 (0) 29 2074 2323Mob: + 44 (0) 7971 231195Email: clarkm@whru.co.ukWeb: www.whru.co.uk

The Wound Healing Research Unit (WHRU) at Cardiff University has aninternational reputation for investigating both acute and chronic human woundsparticularly when these are non-healing or difficult wounds. The WHRU offersservices in clinical care, research and education.

Established in 1991 as the first research unit in the world to specialise in thissubject, the WHRU aims to provide and continue to develop a world-classclinical, scientific and educational wound healing resource for the benefit ofpeople with wound problems. It acts as an interface between healthcareproviders, industry and the academic community to develop models of highquality care based on sound scientific research. The transfer of knowledge toclients is a key objective to ensure that new product development is in line withpatient and clinical needs.Objectives at Medica•Maintain contact with current customers•Meet new commercial organisations where partnership with the WHRU may be

mutually beneficial

Dr Michael ClarkSenior Research Fellow

Ultrawave

Ultrawave LtdEastgate Business ParkWentloog AvenueCardiff CF3 2EYTel: +44 (0) 845 330 4236Fax: +44 (0) 845 330 4231E-mail: admin@ultrawave.co.ukWeb: www.ultrawave.co.uk

Ultrawave have been manufacturing ultrasonic cleaners for over 15 years and are oneof the largest independent UK manufacturers of precision ultrasonic cleaningequipment. Ultrawave’s extensive product range includes benchtop ultrasonic baths,industrial ultrasonic cleaners and custom-designed ultrasonic cleaning systems. AtMedica 07, Ultrawave are exhibiting the Q-Series – a new range of benchtop ultrasoniccleaners which incorporate Frequency Leap technology to provide improved cleaningresults. In addition, the Hygea™ 1250, Ultrawave’s HTM2030 compliant ultrasoniccleaner, designed specifically for surgical instrument cleaning, will be exhibi

Centre for Complex Fluids Processing

Centre for Complex Fluids ProcessingUniversity of Wales Swansea, School of EngineeringSingleton Park, Swansea, Wales, SA2 8PP United KingdomTel: +44 1792 295216Fax: +44 1792 295676Mobile: +44 7715419593Email: g.m.coss@swansea.ac.ukWeb: www.complexfluids.swan.ac.uk

The Centre for Complex Fluids Processing is a research centre in the School ofEngineering at Swansea University. The Centre has been active in technology transfersince 1999 targeting environment, biotechnology, biomedical, food and engineeringsectors.

Complex fluids are a major feature of modern industry. Such fluids are extremelydiverse in origin and composition, ranging, for example, from biotechnological materialsand food products to mineral slurries and polymer melts. Underlying this diversity arecertain properties that must be understood if the processing is to be effective andefficient. These include flow behaviour in process equipment, how the components of thefluid determine its overall properties and how individual components may be selectivelyseparated. Such topics are the focus of the Centre for Complex Fluids Processing.Objectives at MedicaTo exploit research outcomes with internationally leading industries and expandcollaboration with leading international research centres.

Ruskinn Technology Ltd

Ruskinn Technology LtdSuite 3, Technium CentreSony Technology CentrePencoed, Bridgend CF35 5HZTel: 01656 868543Fax: 01656 868541Mobile: 07770 284577Email: juliaf@ruskinn.comWeb: www.ruskinn.com

Ruskinn Technology Ltd provides gas controlled incubation systems that constantlylead the way in innovation. The products are continuously refined to meet thechanging and varied needs of the customer.

The Ruskinn brand has existed since 1993 and became part of Biotrace in 2001.Ruskinn Technology Ltd was formed in February 2006 following a management buyout of the brand from Biotrace International.Objectives at Medica•To meet with existing distribution partners•To meet new / potential distribution partners•To understand investigate new products for our direct markets

Julia FosterBusiness Manager

19

Visitors to the British ScienceMuseum saw a prototype of theworld’s most ‘natural’ artificial lungover a six-week period this summer.The first device of its kind, the newartificial lung is unique in being ableto adapt to the body’s changingneeds, closely mimicking thebehaviour of a human lung.

The prototype on display in theAntenna science news gallery wasdeveloped by Swansea-basedbiomedical devices company HaemairLtd, working with researchers atSwansea University with funding fromEPSRC. The basis of the device is ablood/air mass exchanger that takescarbon dioxide from the blood andtransfers oxygen into the blood. It iscompact, portable and suitable forconscious, active patients.

The device differs from currentExtracorporeal Life Support (ECLS)systems in that is uses only naturalair (rather than bottled or pipedgases). It is also integrated with thenatural respiratory control system sothat transfer rates of oxygen andcarbon dioxide respond naturally tophysical activity. The use ofspecifically coated hollow fibre and/orflat sheet polymers within the massexchanger avoids blood clots withoutthe excessive use of anticoagulantdrugs.

Unlike most conventional treatmentsfor lung deficiency, the device doesnot use the lungs: it allows deficientlungs to rest and recover, rather thanforcing damaged lungs to work harderthrough mechanically supportedbreathing. There is no comparablealternative device.

The Haemair mission is to produce arange of respiratory aids based onthis device, from ones that supportrespiration for patients with deficientlungs - via an easily reversible fullyexternal device - to a prosthetic devicethat may replace human lungs. Thedevice is aimed at both acute andchronic lung conditions, offering hopeto the one million people per year inEurope and North America alone whocurrently die of lung disease ordamage.

In the shorter term, the device hasapplications in the emergencytreatment of patients with recoverablebreathing failure such asthma, ortrauma where lung function isseverely impaired. It can be used intemporary but more enduringconditions, for example over a coupleof weeks for treatment of patientswith Acute Respiratory Infection (ARI),which currently kills 4 million peoplea year.

In the medium term, the device canact as a bridge for patients on lungtransplant waiting lists who sufferfrom emphysema and cystic fibrosis.Currently, about 50% of patients die

on the waiting list, and about 30% dieduring or soon after the operation.The device would enable transplantpatients to be fitter and stronger forthe operation, and better able tosurvive it.

In the longer term, Haemair intend todevelop a fully internal device offeringan alternative to transplantation.

Haemair welcomes enquiriesregarding both commercial andacademic collaborations, and isparticularly interested in hearing fromcompanies concerned withmembranes and membrane surfaces,especially anti-thrombogenicsurfaces, non-thrombogenic surfacesand biomimetic surfaces.

Please contact Dr Steve Brown or Dr Bill Johns at the email addressesbelow.

Haemair LtdUnit 212 Digital TechniumSwansea UniversitySingleton ParkSwanseaSA2 8PPTel: 01792 602466Email: sbrown@haemair.com

wrjohns@haemair.comWeb: www.haemair.com

.

Haemair

M e d i c a S p e c i a l 2 0 0 7 S H O W C A S E

18

BB International is one of thecompanies leading the field in thedevelopment of point-of-care (POC)test diagnostics. Until recently, beingtested for a condition to establish adiagnosis meant waiting for resultsto be processed by a centrallaboratory. But the new generationof POC diagnostic kits enableclinicians to confirm a diagnosis inminutes.

POC testing enables high-prevalenceconditions such as HIV and influenzato be controlled more effectively, andis increasingly used as an earlyscreening device for patients that maybe pre-disposed to certain conditions,so that they can receive preventativetherapy before the illness takes hold.

BBI, a South Wales-based provider ofproducts and services for the globaldiagnostics market, is strategicallypositioned within the POC sector,estimated at $3 billion and identifiedas one of the fastest growing areas ofthe £23 billion ‘in-vitro’ diagnosticsmarket. Manufacturers of laboratory-based tests are now looking to moveinto the POC industry, and BBI canhelp them to do so.

The company was founded in 1986,and following an MBO in 1999, hasbuilt a blue-chip customer base ofdiagnostic companies. BBI supplieshigh quality reagents that customersuse in the development of their owntests. The company’s ‘secret recipe’gold colloid is the raw material thatgives the ‘positive’ line as the visualindicator on a rapid test kit. ‘POCkit’: Opening the door on

point-of-care technology

BBI also works with companies todevelop such tests, and offers a fullrange of research, developmentmanufacturing services from itsCardiff Headquarters, along withfacilities in Dundee and Wisconsin,USA. The company has worked withpartners on a number of testdevelopment projects, many of whichhave FDA approval, and estimatesthat BBI products have featured inaround 4.5 billion diagnostic testsglobally.

BBI has worked on a number ofprojects where a company wishes todevelop an existing Enzyme LinkedImmunosorbent Assay (ELISA) to aless time-consuming and moreversatile diagnosticplatform. ELISAsare a common andusually laboratory-based form ofdiagnosis, and areoften the onlyoptions for patienttesting.

The key and oftenmost costlycomponent of anELISA is the proteinused for detection.By turning theirsuccessful ELISAplatform into a rapidtest, ELISAmanufacturers canmaximize return onthis valuablecomponent. As aspecialist in the field, BBI offers thema flexible solution in an efficient and

cost-effective development service,which includes a detailed feasibilitystudy to ascertain the suitability of theprotein for use in the development ofa lateral flow assay.

In a recent collaboration with aNetherlands organisation, BBIdeveloped a rapid lateral flow assayfor the detection of IgG antibodies to apeptide marker for RheumatoidArthritis (‘RA’). For this BBI usedtheir POCkit® platform, an off-the-shelf lateral flow platform that canreduce development time by up to sixmonths. The assay provides animportant and early diagnosis of RA,and will be used as a screening aid inconjunction with other laboratory and

clinical findings.

BB International

M e d i c a S p e c i a l 2 0 0 7 S H O W C A S E

20

The innovation of rapid moleculartesting is enabling new ways tocombat the spread of MRSA(methicillin-resistant Staphylococcusaureus) infections. JMJLaboratories, a part of the SynergyHealthcare group, is using thistechnology to provide rapidscreening for MRSA.

Within the healthcare sector,screening for the presence of MRSA isbecoming increasingly important aspart of the drive to reduce incidencesof the disease. MRSA killsapproximately 5,000 people in the UKeach year, and there were 3,500episodes of MRSA reported betweenOctober 2005 and March 2006 alone.Between 5% and 7% of patientsentering hospitals have been shownto be carrying MRSA, and if they areidentified in advance they can betreated in isolation.

JMJ Laboratories’ microbiologydepartment is using a test developedby BD Diagnostics, the BDGeneOhm™ MRSA assay, whichdetects a gene sequence that isunique to the drug-resistant strain ofthe organism. The test is performeddirectly on a specimen taken from thepatient’s nasal cavity. A commerciallyavailable instrument (PCR-thermocycler) is used to amplifyMRSA genetic material if present, anddedicated software interprets the datainto a definitive assay result.

The process provides definitive resultswithin two hours of laboratory time ina single assay, as compared to the 24to 72 hours necessary for analysing a

conventional microbiology-basedculture. Results are returnedelectronically, and the timeline fromsample receipt to delivery of results tothe client is less than four hours.

Because this rapid test leads to fasterdetection of MRSA colonisation inpatients, it enables hospitals toimplement swift, appropriateinterventions which can prevent thetransmission of infection, limit thecosts associated with complicationsand treatment, and improve patientoutcomes.

BD Diagnostics have also recentlyobtained European CE Mark approvalfor their GeneOhmTM StaphSR assay,which will enable physicians toimplement the right treatment earlierfor patients with bloodstreaminfections. JMJ is pleased to beworking with BD and can look forwardto implementing their tests fordetection of other serious infectionsincluding Clostridium difficile,

vancomycin-resistant Enterococci andNorovirus.

JMJ Laboratories is a market leaderin the field of clinical pathology andalso in drugs abuse testing, holdingUKAS accreditation for all appropriatetests and providing a nationwideservice. Synergy Healthcare is one ofthe largest UK listed healthcarebusinesses with a long-establishedreputation in the field of infectionprevention and control, and is aleading provider of outsourcedhealthcare support services within theUK, Europe and Asia.

JMJ Laboratories

23

With new multi-million-pound,state-of-the-art manufacturing andR&D facilities in Cardiff, MolecularLight Technology Research issubstantially expanding its portfolioof products and services. Thecompany will begin production ofinnovative medical and industrialdiagnostic test kits for Gen-ProbeInc. for its global markets, and willnow for the first time be able to offercontract manufacturing services tocGMP standards for other companiesand organisations.

‘We are working closely with partnersto ensure that they gain maximumbenefit from outsourcing theirprocesses to Molecular LightTechnology Research,’ explainedInternational Operations ManagerDamien Lucas. ‘We are able toaccommodate a range of scenariosfrom companies at the processdevelopment and pilot scale stage,right through to those requiringhigher volume processing and filling.’

The new facilities were opened byProfessor the Baroness Finlay ofLlandaff, President of the RoyalSociety of Medicine, in May this year.The expansion followed an investmentof £2.9 million by parent companyGen-Probe Inc., and marked the startof plans to double turnover over thenext five years.

Molecular Light Technology Researchwas acquired by Gen-Probe Inc in2003, as a platform both for furtherR&D technology development and todevelop it into an internationalmanufacturing centre.

Established in 1991 as a spin-outfrom the University of Wales Collegeof Medicine (now Cardiff UniversityMedical School) Molecular LightTechnology pioneered thedevelopment of highly sensitivediagnostic tests employing moleculartechnologies. Its chemiluminescenttechnology has been licensedexternally, including in the USA, withFDA approval secured forchemiluminescence-based diagnostictests. These tests are incorporatedinto products used worldwide,including 80% of all US blood banktesting for HIV and hepatitis C (HCV).

Molecular Light Technology is alreadya Welsh biotech success story, withmembers of its R&D teamresponsible for 15 patents and over 80published papers. ‘With the openingof the new facilities,’ said ManagingDirector Dr Molly Price-Jones, ‘thecompany is embarked on the nextphase of its development as aninternational manufacturing centre ofexcellence in diagnostic test systems.’

Molecular Light Technology now aimsto partner biotech innovators andsuppliers in both this growing Welshsector and across the rest of the UK.

The development demonstrates thestrength of diagnostics in Wales thatattracts major internationalcompanies. Diagnostic productmanufacture is a highly regulated andhigh-capital-cost activity andtherefore one which many smallercompanies find prohibitive. Theexpanded facilities enable MolecularLight Technology Research to provideup-and-coming Welsh companieswith just the services to support thatactivity.

Molecular Light Technology Ltd5 Chiltern CloseCardiff Industrial parkLlanishenCardiff CF14 5DL

Tel: 029 2074 7033Fax: 029 2074 7118Email: info@mltresearch.comWeb: www.mltresearch.com

Molecular Light Technology Research

Dr Ian Weeks, Director of Technology, shows the light emitted from thechemiluminescent reaction to Molly Price-Jones and Damien Lucas.

25

M e d i c a S p e c i a l 2 0 0 7 S H O W C A S E

24

Leading-edge product design anddevelopment centre PDR has justbecome the first design company inWales to receive an InternationalDesign Excellence Award (IDEA).The award was for its outstandingdesign work on a bariatric hospitalbed, the ProAxis Plus, developed forNightingale Beds.

Most bariatric beds fail to considerpatient and carer health risks. TheProAxis Plus has been cleverlyengineered to maintain a functionalitythat is among the safest, most user-friendly and most practical on themarket. Its ergonomically designedmattress and electronically controlledfunctions optimise patient comfortwhilst alleviating the potential formanual handling injuries.

Since its launch, the product hasincreased Nightingale’s sales figuresby 286%. Nigel Quinn, ManagingDirector of Nightingale Bedscommented, ‘Since The ProAxisPressure Area Care System wasintroduced into the market, theresponse to date has exceeded allour expectations. The quality ofPDR’s work throughout the projectproved to be exceptional and theirsupport through all phases was firstclass’.

With over 1,600 entries from 30countries, winning an IDEA is theultimate compliment from the designindustry and defines a design as thevery best in business. Winners areselected by a panel of top

international designers and onlypioneering products that have theability to thrive in global markets areselected. Other notable winners thisyear include Apple and Kodak.

PDR has bagged a total of fiveprestigious international awards overthe past two years – more than anyother UK company. Part of theUniversity of Wales Institute, Cardiff(UWIC), PDR is one of the UK’sleading centres for product designand development and is a WelshAssembly Government-designatedCentre of Excellence for Technologyand Industrial Collaboration (CETIC).

Jarred Evans, Commercial Director ofPDR commented, ‘With this award ourtalented team have bestedcompetition from some of the world’smost innovative companies. I amdelighted to showcase the exceptionalexpertise we have at PDR and inWales at this international level’.

PDR’s facilities and equipment arerecognised as some of the best in theUK, and include Computer AidedDesign (CAD) facilities; three rapidprototyping systems; 3D-scanning;CNC machining centres; injectionmoulding; low volume batchmanufacturing facilities; and expertgraphic design and marketing supportservices.

With these in-house resources andcapabilities PDR can take productsfrom concept through to successfulproduction and launch. Servicesinclude developmental research,product design and development,prototyping, low volume rapidmanufacture, graphics, marketingand branding.

For further information contactAngela Spiteri on 029 2041 6725.

PDRThe University of Wales InstituteCardiffWestern AvenueCardiffCF5 2YBTel: 029 2041 6668Fax: 029 2041 7080Email: info-pdr@uwic.ac.ukWeb: www.pdronline.co.uk

The National Centre for Product Designand Development Research (PDR)

Wound Healing Research UnitThe treatment of chronic woundssuch as pressure ulcers and diabeticfoot ulcers is big business. Recentestimates suggest that the NationalHealth Service annually spendsbetween £2.3 billion and £3.1 billionon their treatment – approximately3% of the total expenditure onhealth – even before including thecost of surgical wounds, traumaticwounds and burns.

The Wound Healing Research Unit(WHRU) at Cardiff University is one ofthe largest specialist wound healingcentres worldwide. WHRU seeks toanswer the fundamental questions:

● Which interventions are truly effective?

● How can we best intervene tooptimise the wound environment topromote healing?

● How should wound care beorganised within the NHS tomaximise clinical and economicoutcomes?

● How are health care professionalsbest prepared and educated to healwounds effectively?

Established in 1991, the WHRU wasthe first research unit in the world tospecialise in this subject. It has aninternational reputation forinvestigating both acute and chronichuman wounds, particularly non-healing or difficult wounds. Offeringproducts and services in clinical care,research and education it aims toprovide a world-class wound healingresource for the benefit of people withwound problems.

Accredited as a Centre of Excellencefor Technology and IndustrialCollaboration (CETIC) by the WelshAssembly Government, the WHRUacts as an interface betweenhealthcare providers, industry and theacademic community to developmodels of high-quality care based onsound scientific research. Thetransfer of knowledge to clients is akey objective to ensure that newproduct development is in line withpatient and clinical needs.

WHRU has been working inpartnership with manufacturers bothlocal to Wales and throughout the UKas well as with global organisations,to explore prototypes in thelaboratory, identify potential clinicalbenefits and follow through toleadership of multinational clinicaltrials.

In autumn 2007 the WHRUsuccessfully bid for funds to helpestablish a Welsh Wounds SpecialInterest Group, as a focus for

collaboration between academics,clinicians and the biotechnologycommercial sector. The WelshWounds Special Interest Group offersreal potential for closer collaborationand new partnerships, and willshowcase the value of working inWales for organisations andindividuals with interest in woundsand wound healing.

If you would like further informationon the work of the Wound HealingResearch Unit and the Welsh WoundsSpecial Interest Group, please phoneor email us at the address below.

Wound Healing Research Unit(WHRU)School of MedicineCardiff UniversityHeath ParkCardiff CF14 4XNTel: 029 2074 4505Fax: 029 2075 6334Email: admin@whru.co.ukWeb: www.whru.co.uk

M e d i c a S p e c i a l 2 0 0 7 S H O W C A S E

26

Zarlink SemiconductorZarlink Semiconductor has joinedthe European SHIFT Project (SmartHigh-Integration Flex Technologies)to develop flexible, highly integratedpackages for emergingelectronicconsumer systems,including medical devices, portablecommunication tools, smart cardsand aerospaceutomotiveapplications.

Co-funded by the EuropeanCommission, the SHIFT Projectconsortium consists of R&Dinstitutes, industrial flexmanufacturers, end-users and atechnology support agency. Zarlink’sparticipation in the SHIFT Project isbased in its Caldicot, UK site. Thecompany’s work will be initiallyfocused on developing flexiblepackaging technology for the personalmedical device market. The firstSHIFT-enabled product demonstratorfrom Zarlink will be available at theend of 2007.XX year.

With the increase in electronicssystems that are located near, on oreven implanted in patients, productmanufacturers are seekinglightweight, flexible and compactdesigns to increase productfunctionality, user comfort andconvenience. The embedding ofcomponents in flexible materials suchas polyimides will be used as thebasis of these products. To boost thecombination of high functionality andcompactness as well as user comfort,there is a need for substantialdevelopment in the use of embeddedcomponents in flex substrates.

‘Medical electronic systems that movealong with the user increasinglyrequire more functionality, and mustbe extremely small, lightweight andavailable at a reasonable price,’ saidDavid Heatherall, external projectleader at Zarlink’s Caldicot facility.‘This trend is just starting and it’sclear that we need to advance ‘smart’packaging technology, which meansdeveloping a flexible multilayerstructure supporting multiplefunctions.’

Zarlink’s Caldicot facility is a leader inadvanced micropackaging solutionsfor medical, high reliability andsecurity markets. It offers unique SIP(system-in-package)solutions thatgive customers the flexibility toincorporate a higher componentscount and greater functionality in asmaller space than that typicallyfound in conventional electronicassemblies. Zarlink’s micro-packingexpertise is at the heart of mission-critical and cutting-edge medicaldevice applications.

Zarlink’s combined ultra-low powerand RF (radio frequency) designknow-how is enabling a wide range ofadvanced healthcare products,including the world’s firstswallowable camera capsule andwirelessly enabled implanted medicaldevices supporting new monitoring,diagnostic and therapeuticapplications.

Zarlink Semiconductor Castlegate Business Park Portskewett, Caldicot NP26 5YW Tel: 01291 435300 Fax: 01291435291Email: Ed Goffin, Media Relations

edward.goffin@zarlink.comMartin McHugh, Business Development

martin.mchugh@zarlink.comIan James, Business Development

ian.james@zarlink.comWeb: www.zarlink.comWeb for SHIFT project:

www.shift-project.org

“Medical companies should have a quicker, easier and lower cost way of getting wireless technology to market”

Zarlink’s Microelectronics division delivers, with:• Proven micro-packing expertise supporting

smaller, faster and more reliable technologies

• End-to-end design knowledge ensuring faster time-to-market

• Manufacturing capabilities meeting worldwide medical standards

Wireless Technology for Medical Systems

6ZS3

85

h t t p : / /m i c r o . z a r l i n k . c om

Zarlink Semiconductor—MicroelectronicsPhase 2, Castlegate Business ParkPortskewett, Caldicot, Monmouthshire NP26 5YWTel: +44 (0) 1291 435300

The future is flexible at Zarlink Advanced Packaging Business.